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1. Introduction
Epilepsy is one of the most common neurological disorder, that affects approximately 50
million people in the world and 90% of epilepsy cases are seen in the less developed coun‐
tries[1,2].Epilepsy and seizures affect nearly 3 million Americans of all ages.Inheritance as
etiology for epilepsy has been suspected for centuries. Despite the frequency of seizure dis‐
order and epilepsy little progress has been made in understanding the genetics and physio‐
logical basis of epilepsy until the past two decades.
There has been strong evidence of genetic influence in some epilepsy syndromes from twin
studies. The monozygotic twins have identical genotype and dizygotic twins are genetically
similar like any two siblings and environmental factors are held to minimum in these stud‐
ies. There is consistentlyhigher concordance rates seen in monozygotic than dizygotic
twins.The rates of concordance range from 10.8% in monozygotic twins with brain injuries
to 70% in those without. In dizygotic twins the concordance rate is 3 to 10% [3,4].
Epilepsy is defined as recurrent unprovoked seizures[1].Seizures are unprovoked when
there are no immediate precipitating factors (although an injury to the central nervous sys‐
tem may have occurred in the past) [5].Clinically epilepsy can be divided into two categories
of seizure types: generalized and partial epilepsy. Generalized seizure refers to a condition
when the entire brain is seizing from the onset of the event. Partial seizures describe condi‐
tion when seizure activity starts from a localized brain region and has potential to spread to
other areas of the brain.
The etiology of epilepsy can be divided into three categories, idiopathic, cryptogenic, and
symptomatic. About 25% of epilepsies are associated with injuries to the central nervous
system or gray matter like trauma, CNS infection, stroke, bleed, cerebral palsy, metabolic in‐
sults, etc. These types of epilepsy are classified as symptomatic according to the Internation‐
al Classification of Epileptic Syndromes. The remainder of cases are categorized as
idiopathic or cryptogenic. The idiopathic epilepsies are of genetic origin. In the cryptogenic
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syndromes a specific etiology is unknown. However, in many instances in the cryptogenic
group a genetic influence may remain a possibility [6,7].
An important consideration is that epilepsy is often multifactorial and can be result of both ex‐
ternal and internal contributions. Even in symptomatic epilepsies genetics may be a responsi‐
ble or contributing etiology. Seizures are seen in number of congenital neurodevelopmental
disorders with cortical malformations. Tuberous sclerosis (TS) is a type of neurocutaneous
disorder with associated malignant childhood epilepsy. These children may have West syn‐
drome (hypsarrhythmia, mental retardation, and infantile spasm). About 50% of TS cases are
familial and other half are sporadic mutation. It is a dominant mutation of two tumor suppres‐
sor genes TSC1 and TSC2 located on 9q34 and 16p13.3 that cause the disease [8].
Mutations in over 70 genes are found to be etiology for many types of epilepsy. Seizure is an
episodic dysrhythmia of the cerebral cortex marked by abnormal network synchronization.
Some of the inherited errors destabilize neuronal signaling by inflicting primary disorders of
membrane excitability and synaptic transmission, whereas others do so indirectly by per‐
turbing critical control points that balance the developmental assembly of inhibitory and ex‐
citatory circuits. Ion channels play a major role in generating and controlling neuronal
excitability. The mutations of the ion channel can cause hyper- or hypo-excitability of neu‐
rons [9]. Usually channelopathies are associated with idiopathic epilepsy. Human inherited
epilepsy disorders associated with ion channel mutations (Table 1) have been found in volt‐
age- gated channels (Na+, K+, Ca2+, Cl-) and ligand-gated channels (nicotinic ACH recep‐
tors, GABA receptor) [10].
Epileptic disorder Voltage-gated Ion channels Gene, locus
Generalized epilepsy with febrile
seizure plus type 1 (GEFS+)
Sodium channel, beta-1 subunit SCN1B, 19q13.1
Generalized epilepsy with febrile
seizure plus type 2 (GEFS+)
Sodium channel, alpha subunit SCN1A, 2q24
Benign familial neonatal-infantile
seizures (BFNIS)
Sodium channel, alpha subunit SCN2A, 2q24
Benign familial neonatal convulsions Potassium channel, alpha subunit KCNQ2, 20q13.3 KCNQ3, 8q24
Juvenile myoclonic epilepsy
Juvenile absence epilepsy
Childhood absence epilepsy, type 3
Chloride channel CLCN2, 3q27.1
Epileptic disorder Ligand-Gated Ion Channels Gene, locus
Autosomal dominant juvenile
myoclonic epilepsy
GABA-A receptor, alpha 1 subunit GABRA1, 5q34-q35
Autosomal dominant nocturnal
frontal lobe epilepsy
Nicotinic acetylcholine receptor,
Alpha-4 subunit
CHRNA4, 20q13.2-q13.3
Autosomal dominant nocturnal
frontal lobe epilepsy
Nicotinic acetylcholine receptor,
Beta-2 subunit
CHRNB2, 1q21
Table 1. Inherited epilepsy disorders and ion channel mutations.
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Our knowledge in the field of epilepsy has evolved since the discovery of new specific in‐
herited epilepsy syndromes. Causal mutations have been identified for some of these syn‐
dromes.  They  involve  various  ionic  channels:  Na+  channels  in  the  generalized  epilepsy
with  febrile  seizures  plus  (GEFS+),  benign  familial  neonatal  infantile  seizure  is  another
channelopathy  associated  with  Na  channel  mutation,  nicotinic  receptors  in  autosomal
dominant nocturnal frontal lobe epilepsy (ADNFLE), K+ channels in benign familial neo‐
natal convulsions, and GABA-A receptors in autosomal dominant juvenile myoclonic epi‐
lepsy.  In  addition,  other  paroxysmal  neurological  disorders  like  familial  hemiplegic
migraine and episodic ataxia a result of ion channel mutations and are sometimes associ‐
ated with epilepsy [11].
More new genes associated with epilepsy has been reported the past several years and more
mutations with electrophysiological information will emerge. The ion channelopathies
linked to idiopathic epilepsies account for minority of cases. The ion channel mutation are
common cause of rare monogenic idiopathic epilepsies [12]. The knowledge and under‐
standing of genetics of epilepsy is growing rapidly perhaps with more detailed molecular
dissection will have better definitions and explanation of the common epilepsy syndromes.
More and more genetic mutations are being found that contribute to development of epilep‐
sy. Inheritance can be seen in the classical Mendelian fashion: autosomal dominant, autoso‐
mal recessive, X-linked or mitochondrial inheritance [13]. Familial epilepsies can be
inherited in an autosomal dominant (AD), AD with an incomplete penetrance, or autosomal
recessive (AR). Examples of mitochondrial inheritance include wider syndromes, such as
“Mitochondrial encephalopathy, Lactic Acidosis and Stroke-like Episode Syndrome”
(MELAS) and “Myoclonus Epilepsy with Ragged-Red Fiber Syndrome” (MERRF) [14].
However, in most cases the simple Mendelian model does not explain the familial distribu‐
tion of most epilepsy. It is unclear how genetics and environment interact to influence the
risk of developing different types or phenotypes of epilepsy syndromes. There is a large ge‐
netic influence in epilepsy perhaps the complexity stems from the fact that epilepsy is very
heterogeneous, the important genetic and environmental factors may differ across clinically
defined subsets or syndromes [5].
There have been familial genetic linkage studies conducted to understand genetics of fami‐
lial epilepsy syndromes. Gene mutations have been found in multiple epilepsy syndromes
including familial lateral temporal epilepsies, febrile seizures, generalized epilepsy with fe‐
brile seizures plus (GEFS+) and severe myoclonic epilepsy of infancy. Unfortunately, in
many familial types of epilepsy genetic basis of the disease has not been identified including
familial mesial temporal lobe epilepsy and photosensitive epilepsy [15, 16].
2. Generalized epilepsies
Generalized epilepsy with febrile seizures plus (GEFS+)
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In 1997, Scheffer and Berkovic identified GEFS+ as a newly recognized autosomal dominant
epilepsy syndrome [17]. They described a family that had 25 people with generalized epilep‐
sy over 4 generations. Many individuals had febrile seizures past age 6 and/or had general‐
ized afebrile seizures. The afebrile seizure types include atonic, myoclonic, absence and
tonic-clonic seizures and in some partial seizures. Most phenotypes of GEFS+ have normal
intelligence with normal neurological exam and normal brain imaging. In most individuals
seizures stop by mid childhood and in some it persists. The genetic heterogeneity of GEFS+
has been well studied. The first locus was found on 19q13.1 (GEFS1) associated with gene
(SCN1B) encoding sodium channel Beta 1 subunit. Missense mutations on SCN1A,found on
locus 2q24, encoding for sodium-channel voltage gated alpha subunit account for most of
the GEFS+ cases [18, 19]. Defects on SCN2A and GABA receptor subunit can cause the same
or similar condition as well [4].
Febrile seizures are very common, about 5 to 10 % of children under age of 6 can be affected.
The genetic cause of thisis oligo- or polygenic rather than monogenic. There are rare autoso‐
mal dominant pattern identified and gene loci described. The gene locations include FEB1
on chromosome 8q13-q21, FEB2 on19q, FEB3 on 2q 23-q24, FEB4 on 5q14a15, FEB5 on 6q22-
q24 and FEB6 on 18p11.2 [20].
Autosomal Dominant form of Juvenile Myoclonic Epilepsy (JME)
This is a fairly common form of idiopathic generalized epilepsy. Patients with this disorder
have early morning myoclonus and generalized tonic-clonic seizure. Age of onset is during
adolescence. Patients have characteristic EEG showing generalized polyspike and wave dis‐
charges. Missense mutation of the gene GABRA1 encoding the alpha 1 subunit of the GABA-
A receptor was recently found, locus 5q34-q35. This is not detected in the sporadic cases (21).
Childhood absence epilepsy (CAE)
Childhood absence epilepsy is a very common type of generalized epilepsy, making up
about 8% of epilepsycases in school-aged children. The age of onset of seizures ranges from
4-13 years, with a peak at ages 6-7 years. There is family history of epilepsy in approximate‐
ly 30% of patients. However, autosomal dominant pattern of inheritance with age-depend‐
ent penetrance is suspected. This is likely due to multifactorial pattern of inheritance
involving interplay of the environment and genetics. The seizures are characterized by sud‐
den impairment of consciousness lasting for several seconds. The EEG shows classic pattern
of 3-Hz spike-wave discharge during the episodes [4].
One type of childhood absence epilepsy, ECA1, has been linked to 8q24, second type, ECA2,
is caused by mutation in the GABRG2 gene on band 5q31.1. A third type, ECA3, is caused
by a mutation of the chloride-channel gene CLCN2 on band 3q27. There have been reports
of other epilepsy syndromes associated with voltage gated chloride channel mutation in‐
cluding, juvenile myoclonic epilepsy, juvenile absence epilepsy¸ and epilepsy with grand
mal seizures on awakening [27]. The gene is CLCN2 which encodes chloride channel that is
widely distributed in the nervous system and is involved in neuronal excitability.
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3. Partial epilepsies
Familial nocturnal frontal lobe epilepsy
The genetics of this disorder was the first described for inherited idiopathic epilepsy. The
age of onset for autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is adoles‐
cence or young adulthood. Patients have brief motor seizures during non-REM sleep. The
typical duration of seizures are less than 20 seconds with brief awakenings. Patients may
have more prolong seizures. Patients usually complain of being tired during the day and
underestimate the number of seizures. Auras are reported with these seizures including epi‐
gastric and sensory symptoms. A typical seizure may start with vocalization and grunting
followed by hyper-kinetic movements or tonic contractions with clonic jerking. Treatment is
with antiepileptic medication such as carbamazepine with reduction or cessation of seizures,
but not all patients respond well to medication [4, 20].
First mutation in this disorder was identified in 1995, CHRNA4, and mapped to chromo‐
some 20q13.3. More mutations and two other genes associated with this disorder (CHRNA2
and CHRNB2) have been found;these genes encode alpha 4 and beta 2 subunits of the neu‐
ronal nicotinic acetylcholine receptor (nAChR), respectively. The nAChR is member of large
family of ligand-gated ion channels [22].
Benign familial neonatal convulsions (BFNC)
BFNC is an autosomal dominant inherited epileptic syndrome that occurs in the newborns,
onset within first days of life and spontaneously disappears within few months, at most
fourth month of life. Patient has frequent brief seizures in the form of tonic stiffening, apnea,
clonic, and focal movements. In rare cases adulthood epilepsy occurs, less than 10%. Al‐
though it was thought to be a generalized seizure at first, video EEG monitoring found the
disorder is partial type of epilepsy[23].
Mutations in the voltage gated potassium channel genes have been identified in BFNC on
chromosome 20q13.3 (KCNQ2) and more rarely on chromosome 8q24 (KCNQ3). More than
40 mutations have been reported for KCNQ2 and three for KCNQ3 [24]. Potassium channels
are most critical for maintaining resting membrane potentials and enable rapid repolariza‐
tion after an action potential. Mutations in either KCNQ2 or KCNQ3 decrease function of
the encodedpotassium channel.
Benign Familial Neonatal-Infantile Seizures (BFNIS)
This is an autosomal dominant epilepsy disorder characterized by focal afebrile seizures be‐
ginning age 2 days to 6 months and mean age of 11 weeks. The infants are normally devel‐
oped. There have been 8 families reported to have this syndrome. Originally found in a
large North American family. The mutation is in the sodium channel gene, SCN2A [25].
Benign familial Infantile Convulsions (BFIC)
This is another autosomal dominant inherited partial epilepsy syndrome. The seizures occur
between 2 to 20 months and patient is in remission by age 3. Patient has clusters of afebrile
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partial seizures over few days. Patients respond well to antiepileptic medication. This is a
genetically heterogeneous disorder and linked to chromosome 1q23, 2q24, 19q and 16q12q12
loci. It was first described in Japan and then in Italy [26].
Non-ion channel genes in epilepsy syndromes
Most epilepsy genes mentioned above were associated with channelopathies. In 2001 it was
found that non-ion channel genes play a minorrole in etiology of idiopathic epilepsies. Au‐
tosomal Dominant Partial Epilepsy with Auditory Features (ADPEAF) or Familial Lateral
Temporal Lobe Epilepsy (FLTLE)is a rare type of genetic epilepsy caused by mutation in the
LGI1 gene (leucine-rich glioma inactivated gene 1) on chromosome 10q24. This mutation
modulates excitatory neurotransmission. The clinical features of this disorder include com‐
plex partial seizures from the temporal lobe with auditory auras (identifiable voices, music,
buzzing¸roaring, and ringing), ictal aphasia, visual disturbance and secondary generalized
tonic-clonicseizures. The age of onset is variable usually occurs in young adulthood. Usually
the seizures can be well controlled on antiepileptic medications, some patients have sponta‐
neous remission in their 30s and later [28,29].
Progressive myoclonus epilepsy (PME)
PMEs are collection of rare neurogenetic syndromes, and seizures are a predominant feature
of these disorders. Patients usually have triad of myoclonic seizures, tonic-clonic seizures,
and progressive neurological decline often associated with dementia and ataxia. The patho‐
physiology of these disorders is more diverse and mutations detected may affect many func‐
tions such as metabolic, mitochondrial function, and cell migration. Most PMEs are
autosomal recessive in inheritance [30]. Examples of these disorders include Unverricht-
Lundborg disease, Lafora body disease, myoclonic epilepsy with ragged red fibers, denta‐
torubral-pallidoluysian atrophy, and neuronal ceroid lipofuscinoses.
Unverricht-Lundborg disease
Unverricht-Lundborg disease also known as the Baltic myoclonic epilepsy, because of its
high prevalence in that region is a typical example of progressive myoclonus epilepsy. It is
characterized by generalized seizures, myoclonus, and progressive neurological deteriora‐
tion including dementia and ataxia. The disease was first described by Unverricht in Estonia
in 1891 and by Lundborg in Sweden in 1903. The onset of disease is between ages of 6 and
18. It is autosomal recessive disease mapped on to chromosome 21q22.3. At this time few
point mutations have been identified in the CSTB gene (Cystatin B). Cystatin B is found to
be involved in normal maintenance of neuronal structure and loss of it in mouse models
caused increased proteolysis, apoptosis, and gliosis [31]
Lafora body disease
Lafora body disease is a polyglucosan storage disease, first described in 1911 by Lafora and
Glueck. It is an autosomal recessive disease; linkage to chromosome 21 and chromosome
6p23-25 have been found. The gene encoding novel protein tyrosine phosphatase called La‐
forin has been identified. Laforin is involved in development and maturation of neuronal
networks [32]. This is a rare neurodegenerative disease most patients with this disease do
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not live past their 20s. Onset of symptoms late childhood or adolescence and become pro‐
gressively worse over time
Myoclonic epilepsy and ragged-red fiber disease (MERRF)
This is a mitochondrial disease that affects individuals before age of 20. Patients have ataxia,
hearing loss, poor night vision, and myoclonic seizures.This is maternally-inherited muta‐
tion at position 8344 in the mitochondrial genome in over 80% of cases. Lactic acidosis and
ragged-red fibers on muscle biopsy are diagnostic. Clinical presentation of mitochondrial
disorders is very heterogeneous ranging from impairment in single tissue to encephalopa‐
thies, myopathies, cardiomyopathies and other complex multisystem disorders [14, 33].
Dentatorubural-pallidoluysian atrophy (DRPLA)
DRPLA is a rare autosomal dominant disorder. The symptoms of this disease start in infan‐
cy to early childhood.The disease is from the trinucleotide (CAG) expansion on chromosome
12p. Patients presents with ataxia, myoclonus, dementia and seizures. The severity of the
clinical manifestation depends on the length of the unstable trinucleotide repeat [34].
Neuronal ceroidlipofuscinoses (NCL)
NCL are autosomal recessive neurodegenerative disorders result in storage of lipopigments
in brain and other issues. It is a type of lysosomal storage disease. Clinical manifestation in‐
cludes behavioral changes, seizures, visual problems, decline in mental function, and loss of
motor function. There are different subtypes according to age of onset, pathology and genet‐
ic linkage.
Infantile NCL (CLN1) presents at about 12 months with developmental regression, myoclo‐
nus, ataxia, and visual problems. The genetic defect in CLN1 is identified in the palmitoyl-
protein thioesterase gene (35). Late infantile NCL (CLN2) have similar clinical findings as
CNL1 by age 2-4 years, patient may have intractable epilepsy. The gene found in most cases
is in chromosome 11p15. Juvenile NCL (CLN3) also known as Batten disease is the most
common neurodegenerative disorder of childhood. Clinical finding includes visual loss at
age 5 to 10years and gradual mental decline and seizures. CLN3 maps on chromosome
16p12.1. The CLN3 protein alters metabolism of proteins important for cell function. Adult
NCL (CLN4) is a rare subtype and distinguished from others by absence of ocular manifes‐
tation. CLN5 and CLN6 are variants of the late-infantile NCL. [4, 36]
4. Pharmacogenetics and epilepsy
There is an inherited variance in drug sensitivity among patients; people react to the same
medication differently. Pharmaco-dynamics and kinetic mechanism may be able to deter‐
mine person’s response to medication or adverse reaction. Genetic differences of receptor
subunit may influence response to antiepileptic medications. Studies have shown that re‐
sponse to benzodiazepine can be genetically altered [37]. Current advances made in genetics
can allow modulations of channel function. Targeting channels may be a successful way to
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produce antiepileptic medications. Certain antiepileptic drugs affect different ion channels.
Dilantin is an example of antiepileptic drug that inhibits voltage gated NA channel. There is
hypothesis that alteration of the channel after mutation of a subunit may alter responsive‐
ness to this medication [38]. However, some GEFS+ patients respond well to Dilantin so the
mutation does not alter effectiveness of the medication. More systemic studies need to be
completed to better understand this and this may be an important area of investigation [11].
Pharmacokinetics can affect drug resistance in epilepsy. Multidrug resistance (MDR) means
resistance to structurally and functionally different agents. The MDR-1 gene encodes a mem‐
brane protein, p-glycoprotein, which functions to transport molecules across membranes. In‐
creased expression of this is seen in brains of patients with intractable epilepsy [39].
5. Conclusion
As field of genetics of epilepsies continues to advance the genetic heterogeneity of epilepsy
syndrome has become more apparent.There is heterogeneity in etiology and clinical mani‐
festation of epilepsy[40]. In addition, different genes and mutations may cause the same
seizure phenotype. The discovery of dysfunction of ion channels, channelopathies, account
for many forms of inherited or idiopathic epilepsies as ion channels are critical for normal
neuronal excitation. The progress made in understanding genetic of epilepsies will contrib‐
ute to our ability to recognize and diagnose diseases, provide genetic counseling, potentially
find new treatments and anticonvulsant medications.
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